Alzheimer's disease (AD) is a leading cause of age-related dementia that is characterized by an extensive loss of neurons and synaptic transmission. The pathological hallmarks of AD are neurofibrillary tangles and deposition of β-amyloid (Aβ) plaques. Previous research has investigated how Aβ fragments disrupt synaptic mechanisms in the vulnerable regions of the brain. There is a tremendous potential for stem cell technology to extend upon this research, not only in terms of developing therapeutic applications, but also in modeling AD. Indeed, the advent of induced pluripotent stem cell technology has opened up exciting new avenues for generating patient and disease-specific cell lines from somatic cells that may be used to model AD. Amyloid precursor protein (APP) is a key protein in neuronal development and this article reviews the role of APP in AD. Stem cell technology offers the opportunity to make use of APP in the directed differentiation of induced pluripotent stem cells into functional neurons, a process that may help generate a model of AD and thereby facilitate an understanding of the mechanisms underlying this disease.
Get full access to this article
View all access options for this article.
References
1.
AlonsoAD, Grundke-IqbalI, BarraHS, IqbalK. 1997. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A, 94:298–303.
2.
RheinV, SongX, WiesnerA, IttnerLM, BaysangG, MeierF, OzmenL, BluethmannH, DroseSet al.2009. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A, 106:20057–20062.
3.
Jeffery L.Cummings. 2004. Alzheimer's disease. N Engl J Med, 351:56–67.
4.
World Health Organization. 2006. Alzheimer's Disease: The Brain Killer. www.searo.who.int/en/Section1174/Section1199/Section1567/Section1823_8066.htm. 2010 August 25.
5.
XuJ, KochanekKD, Tejada-VeraB. 2009. Deaths: preliminary data for 2007. Natl Vital Stat Rep, 58:1–51.
6.
TannenbergRK, ScottHL, WestphalenRI, DoddPR. 2004. The identification and characterization of excitotoxic nerve-endings in Alzheimer disease. Curr Alzheimer Res, 1:11–25.
7.
GoedertM, KlugA, CrowtherRA. 2006. Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis, 9:195–207.
8.
PerlDP. 2000. Neuropathology of Alzheimer's disease and related disorders. Neurol Clin, 18:847–64.
9.
YounkinSG. 1998. The role of A beta 42 in Alzheimer's disease. J Physiol Paris, 92:289–292.
DueringM, GrimmMOW, GrimmHS, SchröderJ, HartmannT. 2005. Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. NeurobiolAging, 26:785–788.
12.
PorayetteP, GallegoMJ, KaltchevaMM, BowenRL, Vadakkadath MeethalS, AtwoodCS. 2009. Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J Biol Chem, 284:23806–23817.
13.
AllinsonTMJ, ParkinET, TurnerAJ, HooperNM. 2003. ADAMs family members as amyloid precursor protein α-secretases. J Neurosci Res, 74:342–352.
14.
FurukawaK, SopherBL, RydelRE, BegleyJG, PhamDG, MartinGM, FoxM, MattsonMP. 1996. Increased activity regulating and neuroprotective efficacy of secretase derived secreted amyloid precursor protein conferred by a C terminal heparin binding domain. J Neurochem, 67:1882–1896.
15.
MattsonMP, GuoZH, GeigerJD. 1999. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP mediated mechanism. J Neurochem, 73:532–537.
16.
MezianeH, DodartJC, MathisC, LittleS, ClemensJ, PaulS, UngererA. 1998. Memory-enhancing effects of secreted forms of the -amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci U S A, 95:12683–12688.
17.
Young-PearseTL, BaiJ, ChangR, ZhengJB, LoTurcoJJ, SelkoeDJ. 2007. A critical function for -amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci, 27:14459–14469.
18.
BilenJ, LiuN, BoniniNM. 2006. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle, 5:2835–2838.
19.
RosenDR, Martin-MorrisL, LuoLQ, WhiteK. 1989. A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor. Proc Natl Acad Sci U S A, 86:2478–2482.
20.
BoniniNM, FortiniME. 2003. Human neurodegenerative disease modeling using Drosophila. Annu Rev Neurosci, 26:627–656.
21.
MarshJL, ThompsonLM. 2006. Drosophila in the study of neurodegenerative disease. Neuron, 52:169–78.
22.
WieseM, AntebiA, ZhengH. 2010. Intracellular Trafficking and Synaptic Function of APL-1 in Caenorhabditis elegans. PLoS ONE, 5:e12790.
23.
GuoQ, WangZ, LiH, WieseM, ZhengH. 2011. APP physiological and pathophysiological functions: insights from animal models. Cell Res, 1–12.
24.
MusaA, LehrachH, RussoVA. 2001. Distinct expression patterns of two zebrafish homologues of the human APP gene during embryonic development. Dev Genes Evol, 211:563–567.
25.
NewmanM, MusgraveFI, LardelliM. 2007. Alzheimer disease: Amyloidogenesis, the presenilins and animal models. (BBA)—Mol Basis Dis, 1772:285–297.
26.
TomasiewiczHG, FlahertyDB, SoriaJP, WoodJG. 2002. Transgenic zebrafish model of neurodegeneration. J Neurosci Res, 70:734–45.
27.
Carvan IiiMJ, SonntagDM, CmarCB, CookRS, CurranMA, MillerGL. 2001. Oxidative stress in zebrafish cells: potential utility of transgenic zebrafish as a deployable sentinel for site hazard ranking. Sci Total Environ, 274:183–196.
28.
AsheKH, ZahsKR. 2010. Probing the biology of Alzheimer's disease in mice. Neuron, 66:631–45.
29.
DuyckaertsC, PotierMC, DelatourB. 2008. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol, 115:5–38.
30.
Giovannini MGSC, ProsperiC, BellucciA, VannucchiMG, RosiS, PepeuandG, CasamentiF. 2002. Beta-amyloid- 742 induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis, 11:257–274.
31.
HarkanyT, De JongGI, SoósK, PenkeB, LuitenPGM, GulyaK. 1995. β-amyloid(1–42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Brain Res, 698:270–274.
32.
de WildeMC, PenkeB, van der BeekEM, KuipersAA, KamphuisPJ, BroersenLM. 2011. Neuroprotective Effects of a Specific Multi-Nutrient Intervention Against Abeta42-Induced Toxicity in Rats. J Alzheimers Dis.In press.
33.
IkedaE, ShibaK, MoriH, IchikawaA, SumiyaH, KujiI, TonamiN. 2000. Reduction of vesicular acetylcholine transporter in beta-amyloid protein-infused rats with memory impairment. Nucl Med Commun, 21:933–937.
34.
CakalaM, MalikAR, StrosznajderJB. 2007. Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. Pharmacol Rep, 59:164–172.
35.
BugosO, BhideM, ZilkaN. 2009. Beyond the rat models of human neurodegenerative disorders. Cell Mol Neurobiol, 29:859–869.
36.
MorrisonJH, HofPR. 1997. Life and death of neurons in the aging brain. Science, 278:412–419.
37.
MerrillDA, RobertsJA, TuszynskiMH. 2000. Conservation of neuron number and size in entorhinal cortex layers II, III, and V/VI of aged primates. J Comp Neurol, 422:396–401.
38.
GazzaleyAH, ThakkerMM, HofPR, MorrisonJH. 1997. Preserved number of entorhinal cortex layer II neurons in aged macaque monkeys. Neurobiol Aging, 18:549–553.
39.
MerrillDA, ChibaAA, TuszynskiMH. 2001. Conservation of neuronal number and size in the entorhinal cortex of behaviorally characterized aged rats. J Comp Neurol, 438:445–456.
40.
KlimanskayaI, ChungY, BeckerS, LuSJ, LanzaR. 2006. Human embryonic stem cell lines derived from single blastomeres. Nature, 444:481–485.
41.
OhtsukaS, DaltonS. 2008. Molecular and biological properties of pluripotent embryonic stem cells. Gene Ther, 15:74–81.
42.
ThomsonJA, Itskovitz-EldorJ, ShapiroSS, WaknitzMA, SwiergielJJ, MarshallVS, JonesJM. 1998. Embryonic stem cell lines derived from human blastocysts. Science, 282:1145–1147.
43.
SidhuKS, RyanJP, TuchBE. 2008. Derivation of a new human embryonic stem cell line, endeavour-1, and its clonal propagation. Stem Cells Dev, 17:41–51.
44.
SidhuKS, RyanJP, LeesJG, TuchBE. 2010. Derivation of a new human embryonic stem cell line, Endeavour-2, and its characterization. In Vitro Cell Dev Biol Anim, 46:269–275.
45.
SidhuKS, WalkeS, TuchBE. 2008. Derivation and propagation of hESC under a therapeutic environment. Curr Protoc Stem Cell Biol, Chapter 1,Unit 1A:4.
46.
TakahashiK, TanabeK, OhnukiM, NaritaM, IchisakaT, TomodaK, YamanakaS. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131:861–872.
47.
GuillaumeDJ, ZhangSC. 2008. Human embryonic stem cells: a potential source of transplantable neural progenitor cells. Neurosurg Focus, 24:E3.
48.
ChungHC, LinRC, LoganGJ, AlexanderIE, SachdevPS, SidhuKS. 2011. Human induced pluripotent stem cells derived under feeder-free conditions display unique cell cycle and DNA replication gene profiles. Stem Cells Dev, 21:206–216.
49.
ZengX, CaiJ, ChenJ, LuoY, YouZB, FotterE, WangY, HarveyB, MiuraTet al.2004. Dopaminergic differentiation of human embryonic stem cells. Stem Cells, 22:925–940.
50.
YanY, YangD, ZarnowskaED, DuZ, WerbelB, ValliereC, PearceRA, ThomsonJA, ZhangSC. 2005. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells, 23:781–790.
51.
ShinS, DaltonS, SticeSL. 2005. Human motor neuron differentiation from human embryonic stem cells. Stem Cells Dev, 14:266–269.
52.
BaylisFE. 1990. The ethics of ex utero research on spare “non viable” IVF human embryos. Bioethics, 4:311–329.
53.
TakahashiK, TanabeK, OhnukiM, NaritaM, IchisakaT, TomodaK, YamanakaS. 2006. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131:861–872.
54.
KimSU, de VellisJ. 2009. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res, 87:2183–2200.
55.
AmbasudhanR, TalantovaM, ColemanR, YuanX, ZhuS, LiptonStuart A, DingS. 2011. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell, 9:113–118.
56.
CaiazzoM, Dell/'AnnoMT, DvoretskovaE, LazarevicD, TavernaS, LeoD, SotnikovaTD, MenegonA, RoncagliaPet al.2011. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature, 476:224–227.
57.
PfistererU, KirkebyA, TorperO, WoodJ, NelanderJ, DufourA, BjorklundA, LindvallO, JakobssonJ, ParmarM. 2011. Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A, 108:10343–10348.
JakelRJ, SchneiderBL, SvendsenCN. 2004. Using human neural stem cells to model neurological disease. Nat Rev Genet, 5:136–144.
60.
NishikawaS, GoldsteinRA, NierrasCR. 2008. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol, 9:725–729.
61.
PrzyborskiSA. 2005. Differentiation of human embryonic stem cells after transplantation in immune-deficient mice. Stem Cells, 23:1242–1250.
62.
BlumB, BenvenistyN. 2008. The tumorigenicity of human embryonic stem cells. Adv Cancer Res, 100:133–158.
63.
Ben-DavidU, BenvenistyN. 2011. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer, 11:268–277.
64.
ThinakaranG, KooEH. 2008. Amyloid precursor protein trafficking, processing, and function. J Biol Chem, 283:29615–29619.
65.
Gakhar KoppoleN, HundeshagenP, MandlC, WeyerSW, AllinquantB, MüllerU, CiccoliniF. 2008. Activity requires soluble amyloid precursor protein to promote neurite outgrowth in neural stem cell derived neurons via activation of the MAPK pathway. Eur J Neurosci, 28:871–882.
66.
CailleI, AllinquantB, DupontE, BouillotC, LangerA, MullerU, ProchiantzA. 2004. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development, 131:2173–2181.
67.
FreudeKK, PenjwiniM, DavisJL, LaFerlaFM, Blurton-JonesM. Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J Biol Chem, 286:24264–24274.
68.
AsheKH, ZahsKR. 2010. Probing the biology of Alzheimer's disease in mice. Neuron, 66:631–645.
69.
Westerman MAC-BD, MariashA, KotilinekL, KawarabayashiT, YounkinLH, CarlsonGA, YounkinSG, AsheKH. 2002. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci, 1:22,1858–1867.
70.
StokinGB, LilloC, FalzoneTL, BruschRG, RockensteinE, MountSL, RamanR, DaviesP, MasliahE, WilliamsDS, GoldsteinLSB. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science, 307:1282–1288.
71.
YanknerBA, LuT. 2009. Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem, 284:4755–4759.
72.
Meyer-LuehmannM, Spires-JonesTL, PradaC, Garcia-AllozaM, de CalignonA, RozkalneA, Koenigsknecht-TalbooJ, HoltzmanDM, BacskaiBJ, HymanBT. 2008. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature, 451:720–724.
73.
TurnerPR, O'ConnorK, TateWP, AbrahamWC. 2003. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol, 70:1–32.
74.
Palmert MRPM, WitkerDS, OltersdorfT, YounkinLH, SelkoeDJ, YounkinSG. 1989. The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Nati Acad Sci U S A, 86:6338–6342.
75.
ZhengWH, BastianettoS, MennickenF, MaW, KarS. 2002. Amyloid [beta] peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience, 115:201–211.
76.
OkamotoT, TakedaS, MurayamaY, OgataE, NishimotoI. 1995. Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J Biol Chem, 270:4205–4208.
77.
BreenKC, BruceM, AndertonBH. 1991. Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J Neurosci Res, 28:90–100.
78.
ChenY, McPhieDL, HirschbergJ, NeveRL. 2000. The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem, 275:8929–8935.
79.
SaboSL, IkinAF, BuxbaumJD, GreengardP. 2001. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol, 153:1403–1414.
80.
MoyaKL, BenowitzLI, SchneiderGE, AllinquantB. 1994. The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. Dev Biol, 161:597–603.
81.
SisodiaSS, AnnaertW, KimSH, De StrooperB. 2001. Gamma-secretase: never more enigmatic. Trends Neurosci, 24:S2–S6.
82.
BuxbaumJD, LiuKN, LuoY, SlackJL, StockingKL, PeschonJJ, JohnsonRS, CastnerBJ, CerrettiDP, BlackRA. 1998. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J biol chem, 273:27765–27767.
83.
PerezRG, ZhengH, Van der PloegLH, KooEH. 1997. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci, 17:9407–9414.
84.
SeabrookGR, SmithDW, BoweryBJ, EasterA, ReynoldsT, FitzjohnSM, MortonRA, ZhengH, DawsonGRet al.1999. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology, 38:349–359.
85.
DawsonGR, SeabrookGR, ZhengH, SmithDW, GrahamS, O'DowdG, BoweryBJ, BoyceS, TrumbauerMEet al.1999. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience, 90:1–13.
86.
PhinneyAL, CalhounME, WolferDP, LippHP, ZhengH, JuckerM. 1999. No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice. Neuroscience, 90:1207–1216.
87.
RossjohnJ, CappaiR, FeilSC, HenryA, McKinstryWJ, GalatisD, HesseL, MulthaupG, BeyreutherK, MastersCL, ParkerMW. 1999. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat Struct Biol, 6:327–631.
88.
GralleM, BotelhoMG, WoutersFS. 2009. Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J Biol Chem, 284:15016–15025.
89.
ChowVW, MattsonMP, WongPC, GleichmannM. 2010. An overview of APP processing enzymes and products. Neuromolecular Med, 12:1–12.
90.
StachelSJ, CoburnCA, SteeleTG, JonesKG, LoutzenhiserEF, GregroAR, RajapakseHA, LaiMT, CrouthamelMC, XuM. 2004. Structure-based design of potent and selective cell-permeable inhibitors of human β-secretase (BACE-1)J Med Chem, 47:6447–6450.
91.
MalamasMS, RobichaudA, ErdeiJ, QuagliatoD, SolvibileW, ZhouP, MorrisK, TurnerJ, WagnerEet al.Design and synthesis of aminohydantoins as potent and selective human [beta]-secretase (BACE1) inhibitors with enhanced brain permeability. Bioorg Med Chem Lett, 20:6597–6605.
92.
NawrotB. 2004. Targeting BACE with small inhibitory nucleic acids-a future for Alzheimer's disease therapy?Acta Biochim Pol, 51:431–444.
93.
KuhnHG, SvendsenCN. 1999. Origins, functions, and potential of adult neural stem cells. Bioessays, 21:625–630.
94.
ThinakaranG, BorcheltDR, LeeMK, SluntHH, SpitzerL, KimG, RatovitskyT, DavenportF, NordstedtCet al.1996. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron, 17:181–190.
95.
ŠestanN, Artavanis-TsakonasS, RakicP. 1999. Contact-dependent inhibition of cortical neurite growth mediated by notch signaling. Science, 286:741–746.
96.
PoiraziP, MelBW. 2001. Impact of active dendrites and structural plasticity on the memory capacity of neural tissue. Neuron, 29:779–796.
97.
ShorsTJ, MiesegaesG, BeylinA, ZhaoM, RydelT, GouldE. 1995. Neurogenesis in the adult is involved in the formation of trace memories. Psychol. Rev, 102:101–130.
98.
HitoshiS, AlexsonT, TropepeV, DonovielD, EliaAJ, NyeJS, ConlonRA, MakTW, BernsteinA, Van Der KooyD. 2002. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev, 16:846–858.
99.
GelingA, PlessyC, RastegarS, StrahleU, Bally-CuifL. 2004. Her5 acts as a prepattern factor that blocks neurogenin1 and coe2 expression upstream of Notch to inhibit neurogenesis at the midbrain-hindbrain boundary. Development, 131:1993–2006.
100.
KabosP, KabosovaA, NeumanT. 2002. Blocking HES1 expression initiates GABAergic differentiation and induces the expression of p21(CIP1/WAF1) in human neural stem cells. J Biol Chem, 277:8763–8766.
101.
KwakYD, MarutleA, DantumaE, MerchantS, BushnevS, SugayaK. 2011. Involvement of notch signaling pathway in amyloid precursor protein induced glial differentiation. Eur J Pharmacol, 650:18–27.
102.
CarlsonME, ConboyIM. 2007. Regulating the Notch pathway in embryonic, adult and old stem cells. Curr Opin Pharmacol, 7:303–309.
103.
ChengP, NefedovaY, MieleL, OsborneBA, GabrilovichD. 2003. Notch signaling is necessary but not sufficient for differentiation of dendritic cells. Blood, 102:3980–3988.
104.
EvinG, SerneeMF, MastersCL. 2006. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs, 20:351–372.
